News Release VacciXcell

Press Release

SINGAPORE AND CHINA, July 19, 2018 – Esco Aster, a contract development and manufacturing organization (CDMO) of Esco Group, today announced the launch of lentiviral vector platform and bioproduction technologies to support the Chimeric Antigen Receptor Therapy (CAR-T) pipeline in China.

ESCO ASTER AND KONKUK UNIVERSITY COOPERATE ON PIG VACCINES IN ASIA

Jul 01, 2018

SINGAPORE AND KOREA, July 01, 2018 – Esco Aster, a leading independent contract development and manufacturing organization with its patent Tide Motion bioreactor technology, has signed a collaborative research agreement with the Konkuk University, Seoul.

Read More

AN EXCLUSIVE INTERVIEW WITH ESCO – FROM CLEANROOMS TO CONTAINMENT SYSTEMS

Jun 20, 2018

Esco Group is a Singapore-based life science company with a diversified portfolio and sales in over 100 countries. As a leading manufacturer of laboratory and biopharma equipment, as well as IVF medical devices, Esco offers tailored solutions that fit the needs of laboratories. Esco Group provides equipment and services to support cutting-edge research as well as commercial manufacturing of biopharmaceuticals in the Life Sciences, Medical and Heal

Read More

There's More to Canada!

Apr 26, 2018

Esco Aster, alongside with Esco VacciXcell will be back for the upcoming International Society for Cell Therapy (ISCT) 2018 at Palais Des Congres de Montreal, Canada from May 2 – 5, 2018.

Read More

Esco Aster and Esco VacciXcell Made It West!

Apr 24, 2018

Esco Aster, a leading CDMO company in ASEAN that utilizes Esco VacciXcell’s Tide Motion technology, jump started the year right. The recently held World Vaccine Congress at Renaissance Hotel, Washington D.C. last April 2-5, 2018 was a huge success, with lots of delegates worldwide brought together for a specific reason.

Read More

ESCO ASTER AND MAX PLANCK INSTITUTE COOPERATE ON RESEARCH OF HUMAN FLAVIVIRUS VACCINES

Apr 01, 2018

Esco Aster, a leading independent contract development and manufacturing organization underpinned by its patent Tide Motion bioreactor technology, has signed a cooperation agreement with the Max Planck Institute (MPI) for Dynamics of Complex Technical Systems, Magdeburg, Germany to develop new techniques for cell-culture based virus production of human flavivirus vaccines.

Read More

VISIT BY MINISTER FOR NATIONAL DEVELOPMENT AND SECOND MINISTER FOR FINANCE, LAWRENCE WONG, TO ESCO SINGAPORE

Jan 31, 2018

Esco Group, a renowned Singapore-based life science company, hosted a visit by the Minister for National Development and Second Minister for Finance, Mr Lawrence Wong on 31st January 2018.

Read More

ESCO ASTER AND NATIONAL UNIVERSITY OF SINGAPORE ANNOUNCE A DEVELOPMENT OF 3D ORGANOIDS MINIATURE BIOREACTOR

Jan 29, 2018

Esco Aster, a leading independent contract development and manufacturing organization underpinned by its patent Tide Motion bioreactor technology, has signed a research collaboration agreement with Department of Biomedical Engineering, National University of Singapore (NUS) to develop a miniaturised 3D organoid bioreactor system that can recapitulate the early stages of brain development...

Read More

ESCO ASTER AND NATIONAL UNIVERSITY OF SINGAPORE ANNOUNCE A DEVELOPMENT OF SINGLE-USE BIOREACTOR-BASED STEM CELLS

Jan 08, 2018

Esco Aster, a leading independent contract development and manufacturing organization underpinned by its patent Tide Motion bioreactor technology, has signed a technology development agreement with National University of Singapore (NUS) to jointly develop a proprietary single-use bioreactor system for production of mesenchymal stem cells (MSCs) as a therapy in bone regeneration.

Read More

ESCO ASTER AND BIOPROCESSING TECHNOLOGY INSTITUTE SIGN MEMORANDUM OF UNDERSTANDING TO INNOVATE ON CONTINUOUS BIOMANUFACTURING PLATFORM

Dec 18, 2017

Esco Aster, a leading independent contract development and manufacturing organization dedicated to Singapore’s R&D ecosystem, has signed a Memorandum of Understanding (MOU) with A*STAR’s Bioprocessing Technology Institute (BTI) to accelerate advanced manufacturing of biological products through efficient and highly scalable bioprocessing platforms.

Read More

ESCO ASTER AND INSTITUTE OF MOLECULAR CELL BIOLOGY ANNOUNCE A COLLABORATION TO ACCELERATE PRECLINICAL DEVELOPMENT OF A HAND FOOT AND MOUTH VACCINE

Dec 07, 2017

Esco Aster, a leading independent contract development and manufacturing organization dedicated to the Singapore's R&D ecosystem, has signed a research collaboration agreement with A*STAR's Institute of Molecular Cell Biology (IMCB). The collaboration will facilitate the quick development and commercialisation of a multivalent vaccine targeting Hand Foot and Mouth Disease (HFMD).

Read More

ESCO ASTER UNVEILED NEW AND IMPROVE TIDECELL® AT A*STAR SCIENTIFIC BIOPOLIS ROADSHOW

Nov 30, 2017

Esco Aster, a leading independent contract development and manufacturing organization dedicated to the Singapore's R&D ecosystem, has unveiled its new and improved TideCell®, CelCradle™ and GlucCell® at A*STAR Research Support Center Scientific Roadshow in Biopolis, Singapore.

Read More

Imagine the Possibilities: From Science to Society

Nov 08, 2017

Esco Aster is strengthening its core in bioprocessing for being one of the exhibitors of the upcoming Research Support Center Scientific Roadshow on November 14, 2017, starting from 9:30 am to 3:30 pm at Epicenter Matrix Biopolis, Singapore.

Read More

Introducing Esco Aster Contract Development and Manufacturing Organization (CDMO)

Jun 15, 2017

A CDMO or Contract Development and Manufacturing Organization is a contractual company that provides services like drug development and drug manufacturing in the healthcare industry. CDMO services running on Esco's VacciXcell are now provided by a new independent company called Esco Aster.

Read More